Free tool · No account
Clinical trials for kidney cancer
Kidney cancer (renal cell carcinoma) trials often combine immunotherapy with targeted drugs. Which fit depends on the subtype and whether the cancer has spread.
391 recruiting trials. Showing a sample.
- recruitingPhase 1NCT05700461
Drug Screening Using Novel IMD in Renal Cell Carcinoma
This research is being done to study the safety and feasibility of implanting and retrieving a microdevice that releases microdoses of 19 specific drugs or drug combinations as a possible tool to evaluate the effectiveness of several cancer drugs against metastatic renal cell ...
Sponsored by Oliver JonasFull details on ClinicalTrials.gov → - recruitingPhase 1, Phase 2NCT04895709
A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors
The purpose of this study is to assess the safety, tolerability, and recommended dose(s) of BMS-986340 as monotherapy and in combination with nivolumab, docetaxel, or Pumitamig in participants with advanced solid tumors. This study is a first-in-human (FIH) study of BMS-986340...
Sponsored by Bristol-Myers SquibbFull details on ClinicalTrials.gov → - recruitingPhase 1, Phase 2NCT05269381
Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors
This phase I/II trial tests the safety and tolerability of an experimental personalized vaccine when given by itself and with pembrolizumab in treating patients with solid tumor cancers that have spread to other places in the body (advanced). The experimental vaccine is design...
Sponsored by Mayo ClinicFull details on ClinicalTrials.gov → - recruitingPhase 1, Phase 2NCT00722228
Autologous and Allogeneic Whole Cell Cancer Vaccine for Metastatic Tumors
This study is based on the finding that tumor cells that are grown in the laboratory can be modified in such a way that, when injected to the patient, they will stimulate his/her immune response. This approach will be evaluated in patients with melanoma and colorectal, gastric...
Sponsored by Hadassah Medical OrganizationFull details on ClinicalTrials.gov → - recruitingPhase 2NCT06948552
Photodynamic Diagnosis of Upper Tract Urothelial Carcinoma Using Fluorescence Endoscopy and Oral 5-ALA
This study is evaluating whether a medication called 5-aminolevulinic acid (5-ALA), approved by the FDA for use in brain surgery, can help improve the visibility of upper tract urothelial tumors during surgery. Patients undergoing ureteroscopic tumor resection will receive 5-A...
Sponsored by Henry Ford Health SystemFull details on ClinicalTrials.gov → - recruitingNCT05548621
A Prospective Study to Evaluate the Implementation of Shared Decision Making Strategy for Renal Cell Cancer (RCC)
The aim of this study is to evaluate the effect of two decision aids for renal cell carcinoma (RCC) on the decision-making process and the quality of the decision.
Sponsored by St. Antonius HospitalFull details on ClinicalTrials.gov → - recruitingPhase 2NCT06161532
Sacituzumab Govitecan With or Without Atezolizumab Immunotherapy in Rare Genitourinary Tumors (SMART) Such as High Grade Neuroendocrine Carcinomas, Adenocarcinoma, and Squamous Cell Bladder/Urinary Tract Cancer, Renal Medullary Carcinoma and Penile C...
Background: Rare tumors of the genitourinary (GU) tract can appear in the kidney, bladder, ureters, and penis. Rare tumors are difficult to study because there are not enough people to conduct large trials for new treatments. Two drugs-sacituzumab govitecan (SG) and atezolizu...
Sponsored by National Cancer Institute (NCI)Full details on ClinicalTrials.gov → - recruitingPhase 2NCT06638931
Agnostic Therapy in Rare Solid Tumors
The ANTARES study is a phase II basket trial designed to evaluate the tissue-agnostic efficacy of the monoclonal anti-PD1 antibody, nivolumab, in patients with advanced or metastatic rare tumors. The study aims to treat rare malignancies with PD-L1 expression (CPS ≥ 10), rega...
Sponsored by Instituto do Cancer do Estado de São PauloFull details on ClinicalTrials.gov → - recruitingPhase 2NCT03581773
Folic Acid Supplement Versus Placebo for Treating Mucositis Adverse Events in Metastatic Renal Cell Carcinoma Patients Receiving Targeted Therapy
FASTERCC: Folic acid supplement versus placebo for treating mucositis adverse events in metastatic renal cell carcinoma patients receiving targeted therapy. A randomized, double-blind trial from the Danish renal cancer group (DARENCA study-4)
Sponsored by Niels FristrupFull details on ClinicalTrials.gov → - recruitingNCT03857373
Renal Cancer Detection Using Convolutional Neural Networks
We aim to experiment and implement various deep learning architectures in order to achieve human-level accuracy in Computer-aided diagnosis (CAD) systems. In particular, we are interested in detecting renal tumors from CT urography scans in this project. We would like to class...
Sponsored by Nessn AzawiFull details on ClinicalTrials.gov →
Data from ClinicalTrials.gov, retrieved 2026-07-13. These are trials worth asking your care team about, not a determination that anyone qualifies. Eligibility is decided by the trial's own doctors.
Refine for your situation
Add whatever you know: an age, a city, a mutation from a pathology report. We'll narrow the list to trials that fit. Describe it in your own words.
Trials for other conditions
What we will never do with your records
This generator runs without an account, and KeptWell itself makes the same promises to every family, regardless of plan or price.
- We won't sell your data.
- Not to advertisers, not to data brokers, not to insurers, not to pharma, not to anyone, in any form, ever.
- We won't train AI models on your records.
- Anthropic (whose Claude model powers KeptWell) is contractually prohibited from training on anything we send them, under a signed Business Associate Agreement.
- We won't lock you in.
- You can export everything in your circle as a ZIP at any time. Cancellation is one click.
Common questions
- Is this kidney cancer trial finder really free?
- Yes. You describe the situation, we search ClinicalTrials.gov and show what matches. No account, no payment, no email required. Nothing you type is saved.
- Does showing up here mean the patient qualifies?
- No. These are trials worth asking your care team about. Every trial has detailed eligibility criteria that the trial's own doctors evaluate, and many depend on test results and treatment history that only your medical team knows in full.
- How current is this list?
- The trials come directly from ClinicalTrials.gov and are refreshed daily. Each result links to the full, live study record, and the finder above always runs a fresh search when you use it.
- What should I do with a trial that looks promising?
- Bring it to your oncologist or care team, and mention the NCT number (the ID that starts with NCT). They can tell you whether it is a genuine fit and refer you to the trial site.
Found trials worth discussing? Keep them next to the records.
The next step is a conversation with the care team, and that goes better when the scans, labs, and trial details live in one place everyone in the family can see. That's what KeptWell is: the binder, but it understands what's inside.
Get started
No password. We'll email you a sign-in link — it works whether you're new here or already have an account.